Share
Some people may be able to take a GLP-1 medicine for diabetes or weight management alongside cancer tablets. Your team needs to check the exact combination first. These medicines can slow the movement of food out of the stomach, reduce appetite and cause stomach or bowel symptoms.
Many combinations with cancer tablets have not been well studied. Do not stop either medicine or change the dose yourself.
This matters whether you have just been diagnosed with cancer or have been taking cancer tablets for years. A medicine that suited you before treatment may need reassessment when your appetite, weight, kidney function or other medicines change.
Which medicines are we talking about?
GLP-1 stands for glucagon-like peptide-1, a hormone in the body. Semaglutide and liraglutide act like this hormone and are used for certain diabetes or weight-management needs. Tirzepatide acts on two hormone pathways, including GLP-1, and needs similar checks. Instructions differ between products. Do not swap an injection for a tablet without advice from your prescriber.
Cancer medicines taken by mouth include chemotherapy tablets, targeted medicines and hormone treatments. Some need to be taken with food; others need an empty stomach. They can also interact differently with other medicines. The useful question is therefore: “Is my exact combination suitable, and how should I take it?”
Bring the medicine boxes or clear photographs showing the name, strength and type of medicine. Include injections, supplements, herbal products, antacids and medicines prescribed outside the cancer clinic.
Another GLP-1 tablet, orforglipron, was approved in the United States in 2026. Its instructions include interactions involving enzymes that process medicines, as well as slower stomach emptying. Your pharmacist therefore needs to check both directions: whether the GLP-1 medicine affects another medicine, and whether another medicine affects the GLP-1 treatment. Approval and availability differ between countries.
Does slower stomach emptying mean cancer tablets will not work?
Not necessarily. When the stomach empties more slowly, another medicine may take longer to reach the blood. This does not automatically mean that less medicine reaches the blood overall, or that the cancer treatment stops working.
A 2024 review found that the GLP-1 injections studied often did not change the total amount of another medicine reaching the blood enough to require a dose change. However, many studies involved healthy volunteers, and direct evidence for cancer-tablet combinations was limited.
It cannot establish safety for every cancer medicine or newer GLP-1 product. Vomiting, poor food intake and previous stomach surgery also need individual consideration.
The prescribing information for tirzepatide advises extra care with some medicines taken by mouth. For these medicines, even a small change in the amount reaching the blood can affect safety or benefit. Ask your cancer pharmacist to check your prescription.
Can I solve the problem by separating the doses?
There is no universal two-hour or four-hour gap that solves every interaction. Moving a weekly injection to another day does not establish that its effects on stomach emptying have disappeared. Timing advice must come from the instructions for the actual medicines and the pharmacist’s assessment.
Semaglutide tablets have particularly important instructions about when and how to take them.
The European Medicines Agency (EMA) product information for Rybelsus specifies taking it after a recommended fast of at least eight hours, with no more than 120 mL of water, and waiting at least 30 minutes before food, drink or other oral medicines. Follow the leaflet for the exact product supplied to you.
Some cancer tablets must be taken with food; others require fasting. Ask for a written schedule if these instructions compete. Do not crush tablets, alter a prescribed fasting period or take an extra dose after vomiting unless your team has specifically instructed you to do so.
Appetite, weight and muscle deserve attention
Losing weight is not always helpful during cancer treatment. Even someone with a higher body weight can lose muscle or struggle to eat enough. Your team should look at what you are eating, how your weight is changing and how well you can manage everyday activities.
A tirzepatide study in people with overweight or obesity found loss of both body fat and lean tissue, which includes muscle and other tissues. The study was not in people having cancer treatment, so it cannot tell us exactly what will happen during chemotherapy. Weight, strength and food intake all need attention.
Tell the team if meals become much smaller, clothes loosen unexpectedly or standing from a chair becomes harder. A dietitian can help you get enough protein and energy from food. Suitable muscle-strengthening exercises may also help you manage everyday activities. Ask what is safe for you.
When nausea, vomiting or diarrhoea overlap
GLP-1 medicines and cancer treatments can both cause stomach or bowel symptoms. A new symptom should not automatically be attributed to the injection: cancer treatment, infection or another illness may need attention.
Report persistent vomiting, inability to keep fluids down, worsening constipation, significant abdominal pain or reduced urine promptly. Dehydration can affect kidney function and the safety of other medicines. Severe, persistent abdominal pain needs urgent assessment rather than simply waiting for the next dose.
Keep a short record of symptoms, meals and the timing of medicines. This can help the team decide whether the problem followed a dose increase, a chemotherapy cycle or another change. Do not repeatedly take additional cancer tablets to compensate for uncertain absorption.
Diabetes care must continue alongside cancer care
Stopping diabetes treatment without a replacement plan can be harmful. Steroids used with cancer treatment can raise blood sugar. Eating less can also change the risk of low blood sugar, particularly if you use insulin or certain diabetes tablets.
Your cancer and diabetes teams should agree who adjusts your medicines and how often you should check your blood sugar.
Ask for a written plan for days when you are vomiting or eating very little. Tell the anaesthetist or procedure team that you take a GLP-1 medicine before sedation or an anaesthetic: slower stomach emptying can matter even when you have fasted. Follow their individual medicine and fasting instructions. Do not invent your own stopping interval.
What should be reviewed before continuing or starting treatment?
- The exact cancer medicine, its dose and how to take it with or without food.
- The reason for the GLP-1 medicine, its current benefit and any recent dose increase.
- Any personal or family history of medullary thyroid cancer, or the inherited condition multiple endocrine neoplasia type 2 (MEN2). For example, the US tirzepatide label says it must not be used in these circumstances. Ask your prescriber to check the exact product and diagnosis.
- Appetite, unintended weight loss, muscle weakness and digestive symptoms.
- Kidney function, glucose readings and other medicines that may interact.
- Whether contraception, an upcoming procedure or a change in eating requires additional advice.
If you use an oral contraceptive, US tirzepatide prescribing information advises switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase. This instruction applies to oral contraception; it is not a rule for every GLP-1 product. Ask which contraception is suitable during your cancer treatment.
Common questions
Should everyone stop GLP-1 treatment when cancer is diagnosed?
No. The decision depends on the exact medicines, diabetes needs, nutritional state and side effects. Arrange a coordinated review rather than stopping automatically.
Are GLP-1 medicines a treatment for cancer?
They should not be used as a substitute for established cancer treatment. The medicine information cited here describes uses such as diabetes care, not treatment of an existing cancer. Research about cancer risk does not prove that these medicines treat cancer.
What is the most useful question to ask my pharmacist?
“Please check these exact medicines together and write down how to take them, what to monitor and whom to contact if I cannot eat or keep tablets down.” A practical shared plan is more useful than a blanket answer about the whole drug class.
Sources and further reading
- Calvarysky B, et al. Drug–Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Safety. 2024;47:439–451. Limited direct oncology evidence; predates orforglipron approval. Read source
- Eli Lilly. Mounjaro (tirzepatide) US Prescribing Information. Revised August 2026. Regulatory prescribing information: interactions, contraindications, gastrointestinal effects, anaesthesia and oral contraception. Read source
- European Medicines Agency. Rybelsus (semaglutide) product information, accessed 15 October 2026. Regulatory source; use the actual local product instructions. Read source
- Muscaritoli M, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition. 2021;40:2898–2913. Read source
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025. DXA substudy; not an oncology trial. Read source
- Ligibel JA, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. Journal of Clinical Oncology. 2022. Read source
- Joharatnam-Hogan N, et al. A guideline for the outpatient management of glycaemic control in people with cancer. Diabetic Medicine. 2022. Read source
- Min JS, et al. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Design, Development and Therapy. 2025;19:3509–3537. Read source
- Eli Lilly. Foundayo (orforglipron) US Prescribing Information. Revised July 2026. Regulatory prescribing information, sections 2.2 and 7; initial US approval 2026. Read source
Medically reviewed and approved by Dr (Prof) Vijay Agarwal
Professor and Lead Consultant – Medical Oncology
